EP517: The Business of Prior Auths: The 401-Level Financial Motive Behind Prior Auths

The 401-Level Financial Motive Behind Prior Auths and Pharma Rebate Contracting Imagine a cheaper, generic, or even clinically better drug that somehow ends up not on formulary at all, or stuck behind step edits and prior authorizations with a higher copay than the pricier brand sitting right next to it. In this solo episode, host Stacey Richter breaks down exactly how that happens, walking through a case study she calls Brand Number 2 versus the formulary's reigning Brand Darling to show how PBM and GPO rebate economics, not clinical need, often decide which drugs patients can access easily and which ones get thrown up against a wall of red tape. This is Episode 517 (EP517) of Relentless Health Value. WHAT YOU'LL LEARN ✅ How a high-volume Brand Darling generating billions in sales and huge aggregate rebates can keep a cheaper, generic, or more effective Brand Number 2 stuck on a nonpreferred tier, behind step edits and prior authorizations, regardless of price or efficacy ✅ Why a structural rebate cliff makes it nearly impossible for a new entrant to unseat an established Brand Darling on formulary, even if that new entrant offers a 99 percent rebate ✅ How rebate dollars a PBM or GPO wants to keep can be relabeled as a data fee, a service fee, or an admin fee, a dynamic also flagged by benefits consultant Robyn Tikia, letting a PBM still claim it passes along 100 percent of rebates ✅ Why a prior authorization is often used as a financial negotiating lever against a manufacturer's rebate offer rather than a clinical determination of whether a patient needs the drug ✅ How regulation such as the Inflation Reduction Act is compressing list prices and collapsing the rebate spread that the traditional contracting math depends on ✅ How GoodRx runs a reverse auction among PBMs to surface its advertised cash price, making coupon sites effectively a sales channel for the same PBMs that lock manufacturers into exclusive formulary contracts WHY THIS MATTERS As Stacey Richter lays it out, a PBM with a fiduciary duty to its shareholders has every financial incentive to double down on a high-volume Brand Darling and freeze out a cheaper or better Brand Number 2 with step edits and prior auths, whether or not that serves the patient stuck in the middle. As regulation compresses list prices and rebate spreads get less stable, more pharma manufacturers are deciding it is worth giving up access to large blocks of insured lives in order to control their own price directly through cash pay, patient assistance programs, or their own copay cards. It is not a clean alternative, since cash pay still runs through PBM-linked coupon platforms like GoodRx, but for some brands it is starting to look like the more controllable bet. === LINKS === 🔗 Show Notes with all mentioned links: https://cc-lnk.com/EP517 ✉️ Enjoy this podcast? Subscribe to the free weekly newsletter: https://relentlesshealthvalue.com/joi... 🫙 Support the podcast with a small donation to the Tip Jar: https://relentlesshealthvalue.com/joi... 📺 Subscribe to our YouTube channel    / @relentlesshealthvalue   🎤 Listen on Apple Podcasts https://podcasts.apple.com/us/podcast... 🎤 Listen on Spotify https://open.spotify.com/show/6UjgzI7... === CONNECT WITH THE RHV TEAM === ✭ LinkedIn   / relentless-health-value   ✭ Threads https://www.threads.net/@relentlesshe... ✭ Bluesky https://bsky.app/profile/relentleshea... ✭ X   / relentleshealth   00:00 Episode Setup 00:48 Why Cash Pay Exists 03:22 Brand Two Case Study 04:20 Rebates Drive Formularies 07:45 Rebate Cliff Exclusion 09:50 Prior Auth As Leverage 11:55 Rebate Game Economics 13:31 Regulation Breaks Math 16:14 Cash Pay Tradeoffs 19:46 PBM Reaction To Direct 20:38 GoodRx Reverse Auction 23:50 Coupon Sites Monetization 26:21 Copay Card Tie In 26:55 Wrap Up And Credits